Literature DB >> 25983779

Bullous dermatosis of childhood induced by gemfibrozil.

Bahareh Abtahi-Naeini1, Hamidreza Sadeghiyan2, Neda Adibi3, Mohammad Reza Shokrollahi4, Mohsen Pourazizi5.   

Abstract

Entities:  

Year:  2015        PMID: 25983779      PMCID: PMC4400721     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


× No keyword cloud information.
Sir, Linear IgA bullous dermatosis (LABD) is an acquired, auto-immune, sub-epidermal, vesiculobullous disease caused by the linear deposition of IgA in basement membrane zone (BMZ).[1] It may be idiopathic or drug-induced, although its pathology is not clearly understood.[2] Its manifestations are similar to those of other blistering diseases, such as dermatitis herpetiformis or bullous pemphigoid. In contrast, these blistering diseases are commonly induced by drugs.[3] LABD represents bimodal age of onset. However, it is more common in the adult because this group is often being treated for multiple medical conditions.[4] There are several reports describing the association of LABD with various drugs.[5] Drug-induced LABD should be suspected when the drug eruption resembles erythema multiforme, dermatitis herpetiformis, or bullous pemphigoid, and vancomycin is one of the more common inducers of LABD.[6] Other drugs include lithium, captopril, penicillins, cephalosporins, nonsteroidal anti-inflammatory drugs (diclofenac and naproxen), oxaprozin, and so on.[6] A 13-year-old girl with no previous history of skin disease was treated for 3 weeks with gemfibrozil for familial hypertriglyceridemia. 3 weeks earlier, some circumferential vesicles and tens bullae as annular erythema were symmetrically noted on the areola of breasts [Figure 1].
Figure 1

Linear IgA bullous dermatosis. The circumferential tens bullae with erythematous annular background in the areola of breasts

Linear IgA bullous dermatosis. The circumferential tens bullae with erythematous annular background in the areola of breasts The lesions were pain-free. Personal and familial history was unremarkable, except for familial hypertriglyceridemia. The nails, mucosae, and hair were normal. All laboratory data were within normal limits. A biopsy specimen revealed sub-epidermal bullae, with the presence of neutrophils in the underlying dermis and few eosinophils. Direct immunofluorescence revealed linear deposits of IgA and IgG at the BMZ. Based on the clinical and immunological results, a diagnosis of drug-induced LABD was made. We suspected gemfibrozil to be the causative drug. Therefore, administration of gemfibrozil was discontinued, and we started the treatment with administration of oral prednisone and anti-histamine (15 mg/day). Lesions remitted 1-month after discontinuing gemfibrozil. A 1-year follow-up revealed neither signs and symptoms nor recurrences. In the case of these medications, they may stimulate the immune system to produce IgA antibodies in a predisposed individual. Drug-induced LABD usually remits within 2-6 weeks of cessation of the drug.[6] In our case, remission completely occurred after 4 weeks. To the best of our knowledge, there is no report on gemfibrozil-induced LABD. Drug-induced LABD may be an immunological response to a drug. Drug-induced type tends to show the transient nature of cutaneous symptoms, lack of mucosal or conjunctival lesions, and rapid improvement after discontinuation of medication and lack of circulating IgA antibodies.[7] It should be treated by discontinuing the suspected drug, but more follow-up may be required.

AUTHOR'S CONTRIBUTION

BA, MP and HS designed the study and were responsible for the overall study management. HS, NA and MS prepared the manuscript. BA and MP conducting the study and revising the draft. All authors approved the final version of the manuscript, and agreed for all aspects of the work.
  7 in total

1.  IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis.

Authors:  Barbara Horváth; Andrea Niedermeier; Eva Podstawa; Ralf Müller; Nicolas Hunzelmann; Sarolta Kárpáti; Michael Hertl
Journal:  Exp Dermatol       Date:  2010-05-25       Impact factor: 3.960

2.  [Chronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone].

Authors:  D Pirkhammer; D Zillikens; D Födinger; P Zimmermann; K Rappersberger
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

Review 3.  Drug-induced linear IgA bullous dermatosis.

Authors:  Hanae Onodera; Martin C Mihm; Aki Yoshida; Toshihide Akasaka
Journal:  J Dermatol       Date:  2005-09       Impact factor: 4.005

Review 4.  Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

Authors:  M A Waldman; D R Black; J P Callen
Journal:  Clin Exp Dermatol       Date:  2004-11       Impact factor: 3.470

5.  Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children.

Authors:  Monia Kharfi; Aida Khaled; Amel Karaa; Ines Zaraa; Becima Fazaa; Mohamed Ridha Kamoun
Journal:  Dermatol Online J       Date:  2010-01-15

6.  Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms.

Authors:  J Chanal; S Ingen-Housz-Oro; N Ortonne; T A Duong; M Thomas; L Valeyrie-Allanore; B Lebrun-Vignes; C André; J C Roujeau; O Chosidow; P Wolkenstein
Journal:  Br J Dermatol       Date:  2013-11       Impact factor: 9.302

Review 7.  Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature.

Authors:  M K Kuechle; E Stegemeir; B Maynard; L E Gibson; K M Leiferman; M S Peters
Journal:  J Am Acad Dermatol       Date:  1994-02       Impact factor: 11.527

  7 in total
  1 in total

Review 1.  Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.

Authors:  Kyeongsoon Kim; Hynda K Kleinman; Hahn-Jun Lee; Kalipada Pahan
Journal:  Orphanet J Rare Dis       Date:  2017-06-17       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.